Key result
Post-discharge LMWH prophylaxis occurs routinely in ~67% of UK cancer centres after major urological surgery.
Cross-Sectional (n=64)
Yes
Answers are grounded in this paper and cite their sources.
OBJECTIVES: To evaluate the use of post-discharge venous thromboembolism (VTE) prophylaxis in UK pelvic cancer centres consistent with national guidelines. METHODS: Data was collected from healthcare professionals from 64 UK pelvic cancer centres. RESULTS: After radical cystectomy (RC), all cancer centres routinely use low-molecular-weight heparin (LMWH) in the perioperative period. After RC 67% of cancer centres use post-discharge LMWH routinely. After radical prostatectomy (RP), 98% of units use perioperative LMWH VTE prophylaxis routinely. After RP, 61% of hospitals always use post-discharge LMWH. In all, 27% of all UK cancer centres reported deaths or serious VTE complications from urological pelvic cancer surgery in the last 2 years. CONCLUSIONS: The National Institute for Health and Care Excellence (NICE) issued explicit guidance of VTE prophylaxis after pelvic and abdominal cancer surgery. Conversion of national guidance into local policy is ≈60% for UK pelvic cancer centres. A lack of good quality evidence is cited as a reason for not adhering to NICE guidance.
No takes yet. Share an insight, caveat, or question.
Pridgeon et al. (2014) conducted a cross-sectional in Venous thromboembolism prophylaxis in urological pelvic cancer surgery (n=64). Post-discharge low-molecular-weight heparin (LMWH) VTE prophylaxis was evaluated on Routine use of post-discharge LMWH VTE prophylaxis after radical cystectomy and radical prostatectomy. Post-discharge LMWH VTE prophylaxis was routinely used in 67% of UK cancer centres after radical cystectomy and 61% after radical prostatectomy, with 27% reporting serious VTE complications or deaths.
Synapse has enriched 10 related papers. Consider them for comparative context: